Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Drugmaker Lilly to Trim Workforce by Nearly 9 Percent

By Tom Murphy AP Health Writer | September 7, 2017

Eli Lilly will slash its global workforce by nearly 9 percent as the drugmaker closes some research sites and pushes to trim fixed costs.

The Indianapolis company said Thursday it will cut about 3,500 positions, mostly through a voluntary retirement program in the United States. The insulin and cancer treatment maker employed 41,240 people worldwide at the end of June.

Lilly will close research and development sites in Bridgewater, New Jersey, and Shanghai. It also will move production from an animal health manufacturing site in Larchwood, Iowa, to another plant.

Chairman and CEO David Ricks said in a statement that his company wants to streamline its business in order to invest in new treatments and capitalize on recently launched drugs. The company expects about $500 million in annual savings from the cuts.

Eli Lilly and Co. has seen sales slump for top sellers like the insulin Humalog, and it has weathered in recent years the loss of patent protection for two of its all-time top selling drugs, the antidepressant Cymbalta and the antipsychotics Zyprexa. That exposed those multi-billion dollar revenue generators to cheaper generic competition.

Lilly also has dealt with some clinical research setbacks, including the failure of a potential Alzheimer’s disease treatment in late-stage studies, the most expensive phase of clinical development.

The company said Thursday that it will book about $1.2 billion in charges before taxes for the workforce cuts. Lilly said the early retirement program, which was announced to employees Thursday, will include enhanced retirement benefits and largely be completed by the end of the year.

The cuts won’t affect Lilly’s adjusted earnings forecast for 2017. The drugmaker said in July it expects full-year earnings in the range of $4.10 to $4.20 per share.

Analysts forecast, on average, $4.16 per share, according to FactSet.

Shares of Lilly climbed 52 cents to $81.05 Thursday morning, while broader indexes slipped. The stock has climbed more than 9 percent so far this year.

(Source: Associated Press)


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE